纳武利尤单抗联合瑞拉利单抗对比纳武利尤单抗单药治疗既往未治的不可切除或转移性黑色素瘤患者的健康相关生活质量:RELATIVITY-047试验
RELATIVITY-047试验中,既往未治的不可切除或转移性黑色素瘤患者随机接受纳武利尤单抗联合瑞拉利单抗固定剂量组合或纳武利尤单抗单药治疗。更新分析(中位随访19.3个月)显示,联合组健康相关生活质量保持稳定,与单药组相似,尽管联合组3或4级治疗相关不良事件发生率更高。
要点
- 联合组健康相关生活质量在治疗期间保持稳定,与纳武利尤单抗单药组相似。
- 联合组3或4级治疗相关不良事件发生率高于单药组,但报告被不良事件相当或非常困扰的患者比例低且两组相当。
- 结果支持纳武利尤单抗联合瑞拉利单抗作为晚期黑色素瘤一线治疗选择。
核心结论
- RELATIVITY-047试验结果显示,纳武利尤单抗联合瑞拉利单抗固定剂量组合相较纳武利尤单抗单药获得的PFS获益伴随稳定的患者报告健康相关生活质量,支持该联合方案作为晚期黑色素瘤一线治疗选择。
研究设计与样本
- II/III期RELATIVITY-047试验,患者随机接受静脉纳武利尤单抗联合瑞拉利单抗(分别为480 mg和160 mg)或纳武利尤单抗(480 mg)每4周一次。
- 健康相关生活质量采用癌症治疗功能评估-黑色素瘤(FACT-M)和EQ-5D-3L问卷在基线、每个治疗周期给药前及随访(治疗后)访视时评估。
- 本次报告为更新分析,中位随访19.3个月。
主要发现
- 与初始分析一致,联合组健康相关生活质量在治疗期间保持稳定,与纳武利尤单抗单药组相似。
- 各量表/子量表较基线的平均变化未超过临床意义阈值,且各评估工具结果一致。
- 尽管联合组3或4级治疗相关不良事件发生率高于单药组,报告被不良事件相当或非常困扰的患者比例低且两组相当。
临床怎么用
- 作者结论支持纳武利尤单抗联合瑞拉利单抗固定剂量组合作为晚期黑色素瘤一线治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the phase II/III RELATIVITY-047 trial, a novel fixed-dose combination (FDC) of nivolumab plus relatlimab (NIVO + RELA; a programmed death-1 and a lymphocyte-activation gene 3 inhibitor, respectively) significantly improved progression-free survival (PFS) versus NIVO in patients with previously untreated unresectable or metastatic melanoma (median follow-up, 13.2 months) with stable health-related quality of life (HRQoL), although grade three or four treatment-related adverse events (TRAEs) were more frequent with the combination. Updated HRQoL results (median follow-up, 19.3 months) are presented. METHODS: Patients were randomised to receive intravenous NIVO + RELA (480 mg and 160 mg, respectively) or NIVO (480 mg) every 4 weeks. HRQoL was assessed using the Functional Assessment of Cancer Treatment-Melanoma (FACT-M) and EQ-5D-3L questionnaires at baseline, before dosing at each treatment cycle, and at follow-up (posttreatment) visits. RESULTS: Consistent with the initial analysis, HRQoL remained stable with NIVO + RELA on treatment and was similar to that with NIVO. Mean changes from baseline did not exceed clinically meaningful thresholds. HRQoL results were consistent across instruments and scales/subscales. Despite an increased rate of grade three or four TRAEs with NIVO + RELA versus NIVO, the proportion of patients reporting that they were bothered 'quite a bit' or 'very much' by TRAEs was low and comparable between treatments. CONCLUSION: Results from the RELATIVITY-047 trial show that the PFS benefit with NIVO + RELA FDC over NIVO was obtained with stable patient-reported HRQoL, supporting NIVO + RELA as a first-line treatment option for patients with advanced melanoma.
引用
- Schadendorf D, Tawbi H, Lipson EJ, et al. Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial. Eur J Cancer. 2023. PMID: 37167764. doi:10.1016/j.ejca.2023.03.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。